A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of perifosine in patients with chondrosarcomas, alveolar soft part
sarcomas and extra-skeletal myxoid chondrosarcomas. Patients will receive perifosine 100 mg
orally qhs with food until disease progression. The goals of this study include:
- In this study a daily dose of perifosine previously determined to be relatively
non-toxic will be evaluated in patients with chondrosarcomas, alveolar soft part
sarcomas and extra-skeletal myxoid chondrosarcomas.
- Response to therapy will be based on regression of measurable disease according to Choi
criteria. Time to progression and duration of stable disease will be measured as
secondary endpoints of the study.
Phase:
Phase 2
Details
Lead Sponsor:
AEterna Zentaris
Collaborator:
Sarcoma Alliance for Research through Collaboration